Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment

Abstract

At sites of thrombosis and vascular injury, interactions occur among platelets, leucocytes and endothelial cells. Patients with peripheral arterial occlusive disease (PAOD) have been shown to have raised total serum cholesterol and serum triglycerides and increased sP-selectin levels when compared with controls. A total of 31 patients with PAOD and hypercholesterolaemia took part in this three-staged study. Soluble P-selectin (sP-selectin) levels were significantly lowered after 12 weeks of fluvastatin treatment (157.0 ng/ml versus 113.77 ng/ml, p = 0.01), whereas 12 weeks of placebo treatment had no statistically significant effect on sP-selectin levels (150.0 ng/ml versus 139.4 ng/ml). An unpaired t-test almost reached statistical significance (p = 0.051) when the levels by which sP-selectin fell after 12 weeks of active or placebo treatment were compared. The placebo group was then put onto long-term, active treatment and sP-selectin levels were significantly lowered by fluvastatin when compared to pre-treatment levels (150.0 ng/ml versus 110.0 ng/ml, p = 0.03). By lowering the levels of P-selectin, fluvastatin may not only attenuate atherosclerotic progression but may also decrease the platelet activation associated with PAOD.

Keywords

atherosclerosis cholesterol endothelium peripheral arterial occlusive disease platelets

References

Calderon TM , Factor SM , Hatcher VB , Berliner JA , Berman JW. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG. Expression in vivo in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels. Lab Invest 1994; 70(6): 836-849.

Faruqi RM , DiCorleto PE. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993; 69: S19-S29.

Numano F , Kishi Y , Ashikaga T , Hata A , Makita T , Watanabe R.

What effect does controlling platelets have on atherosclerosis?

Ann N Y Acad Sci 1995; 748: 383-392.

Holvoet P , Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997; 8(5): 320-328.

Cronstein BN , Weissman G. The adhesion molecules of inflammation. Arthrit Rheum 1993; 36(2): 147-157.

Yeo EL , Sheppard JL , Feuerstein IA. Role of P-selectin and leucocyte activation in polymorphonuclear cell adhesion to surface adherent activated under physiological conditions (an injury vessel wall model). Blood 1994; 83(9): 2498-2507.

Lawrence MB , Springer TA. Leukocytes roll on E-selectin. J Immunol 1991; 151(11): 6338-6346.

Gearing AJH , Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 11: 767-804.

Webb AT , Franks PJ , Reaveley DA , Greenhalgh RM , Brown EA. Prevalence of intermittent claudication and risk factors for its development in patients on renal replacement therapy. Eur J Vasc Surg 1993; 7(5): 523-527.

10.

Kirk G. Cell adhesion molecules: levels, roles and interactions [PhD Thesis]. Dundee: University of Dundee, 1997.

11.

Blann AD , Seigneur M , Boisseau MR , Taberner DA , McCollum CN. Soluble P-selectin in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis 1996; 7(8): 789-793.

12.

Kirk G , Maple C , McLaren M , Belch JJF. A circadian rhythm may exist in healthy controls for soluble P-selectin and platelet count. Platelets 1995; 6: 414-415.

13.

Kirk G , McLaren M , Belch JJF. Soluble P-selectin assay: importance of correct anticoagulant choice. Platelets 1997; 8: 159-162.

14.

MRFIT, The Multiple Risk Factor Intervention Trial Research Group . Mortality after 16 years for participants randomised to the Multiple Risk Factor Intervention Trial. Circulation 1996; 94(5): 946-951.

15.

Davi G , Romano M , Mezzetti A et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97(10): 953-957.

16.

Packman MA , Kinlough-Rathbone RL. Mechanisms of atherogenesis and thrombosis. In: Bloom AL , Forbes CD , Thomas DP , eds. Haemostasis and thrombosis, Volume 2. London: Churchill Livingstone, 1994: 1107-1152.

17.

Rang HP , Dale MM , Ritter JM. Pharmacology. Edinburgh: Churchill Livingstone, 1995.

18.

Furie B , Furie BC. Leukocyte crosstalk at the vascular wall. Thromb Haemost 1997; 78(1): 306-309.

19.

Vora DK , Fang ZT , Liva SM et al. Induction of P-selectin by oxidised lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997; 80(6): 810-818.

20.

Betteridge DJ. Diet and drug treatment of the hyperlipidaemias. Risk 1993; 1(3): 25-28.

21.

Blann AD , Lip GY , Beevers DG , McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77(6): 1077-1080.

22.

Bo M , Bonino F , Neirotto M et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42(2): 106-113.

23.

Osamah H , Mira R , Sorina S , Shlomo K , Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997; 44(1): 77-83.